Home Biotechnology Xbrane Biopharma AB
X

Xbrane Biopharma AB

Profile managed by Bizz Id
Sweden

Description

Xbrane Biopharma AB is a Swedish biosimilar developer working from cell line to approval, with a proprietary platform designed to lower production costs. Its ranibizumab biosimilar Ximluci is approved in the EU, and it is developing nivolumab and daratumumab candidates.

Products

3 products
Daratumumab

Brand: Xdarzane. Darzalex biosimilar candidate (anti-CD38). Multiple myeloma. Preclinical.

Under development

Finished product (FDF)

Verified on 2026-10-21

Daratumumab: see suppliers →

Nivolumab

Brand: Xdivane. Opdivo biosimilar candidate (PD-1 inhibitor). Skin, lung, renal, head and neck, bladder cancer. Clinical phase (registration-enabling study ongoing). Partner: INTAS.

Under development

Finished product (FDF)

Verified on 2026-10-21

Nivolumab: see suppliers →

Ranibizumab

Brand: Ximluci. Lucentis biosimilar (VEGF-A inhibitor). Wet AMD, diabetic macular edema, diabetic retinopathy, RVO. Sold in 20 European and 4 non-European markets with STADA.

Aprobado EMA; Solicitud presentada: FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ranibizumab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free